Oncomine Dx Target Test

In-house testing with first FDA-approved, NGS-based CDx for NSCLC

The Ion Torrent™ Oncomine™ Dx Target Test is the first FDA-approved, next-generation sequencing (NGS)-based companion diagnostic (CDx) that can help you achieve better outcomes for your non-small cell lung cancer (NSCLC) patients. It enables multibiomarker analysis from a single tissue sample to aid treatment decisions in as little as four days.

Bringing the test in-house, instead of relying on third-party laboratories, helps expedite the testing process so you can start treating your patients with the right targeted therapies more quickly.

The Oncomine Dx Target Test is reimbursable, which can help lower patient out-of-pocket expenses, provide hospitals with a beneficial economic model, and position your institution as a treatment center of choice in the community it serves.

We encourage you to discuss in-house biomarker testing with your medical colleagues and fellow hospital leadership members. To facilitate these conversations, we’ve compiled this short guide that highlights key benefits for your hospital’s stakeholders.

Benefit to patients

• Faster actionable testing—Shorter turnaround times for test results help expedite selection of targeted therapies, which can have a positive impact on outcomes for NSCLC patients. Outsourcing your tests to third-party labs can delay results by weeks, time that your late-stage patients can’t spare.

• Fewer repeat biopsies—The Oncomine Dx Target Test enables a full biomarker report from very small tumor samples, reducing the need for second biopsies and avoiding suboptimal therapy selection in the absence of a complete biomarker report.

• Lower out-of-pocket costs—The Oncomine Dx Target Test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. This helps offset expenses and ease the financial burden on your patients.
Benefits to hospitals and medical teams

- **Financial feasibility**—Hospitals that test at least 300 Stage III/IV NSCLC patients per year can benefit from an attractive economic model that makes financial sense for the institution since the Oncomine Dx Target Test is reimbursable. One of our consultants will be happy to walk you through the financial model—just book an appointment.

- **Reputation building**—Improved patient care associated with in-house multibiomarker testing helps position hospitals as a comprehensive treatment center in the local community. Offering full capabilities for precision medicine biomarker testing helps build institutional influence and a reputation as a hospital of choice for NSCLC patients.

- **Improved care coordination**—Gain full flexibility to discuss multibiomarker test results with your lab partners, and the ability to work together with the care team to identify the best strategies for each patient.

- **Develop local expertise**—Given that 73% of drugs in the oncology pipeline are associated with molecular biomarkers,¹ the ability to test is becoming a must for any lab that wants to provide state-of-the-art services to their clinicians and patients. In-house testing enables labs to provide clinicians with fast, flexible, and individualized service.

- **Simple to implement**—As an FDA-approved, end-to-end solution, the Oncomine Dx Target Test is designed with a workflow that is easy to implement and that delivers a clear, annotated report with actionable results in as little as four days. The intuitive software circumvents the need for advanced bioinformatics expertise.

Reference


Are you ready to get started?

Our precision oncology consultants are ready to develop a strategy that will work for your institution.

Find out more at [oncomine.com/dx](http://oncomine.com/dx)

The Oncomine Dx Target Test is for in vitro diagnostic use.

Abbreviated intended use: The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high-throughput, parallel-sequencing technology to detect single-nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGM™ Dx System. For additional information, please visit thermofisher.com/us/en/home/clinical/diagnostic-testing/condition-disease-diagnostics/oncology-diagnostics/oncomine-dx-target-test/oncomine-dx-target-test-us-only.html.

© 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL07546 0918